Trial
NCT03062540
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Tonix Pharmaceuticals, Inc.
Collaborators
Premier Research
Condition
PTSD
Intervention
TNX-102 SL
Why stopped
Stopped early due to inadequate separation on primary efficacy endpoint at Week 12 according to Interim Analysis conducted on the first 274 (50%) patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-22